NCT06607185 2026-03-13A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsEli Lilly and CompanyPhase 1 Active not recruiting750 enrolled
NCT04999761 2024-09-25AB122 Platform StudyTaiho Pharmaceutical Co., Ltd.Phase 1 Recruiting917 enrolled